Practical Geriatric Assessment (PGA) Implementation Strategies and Correlative Evaluations (PACE-70)

Part of paid clinical trials in Princeton, New Jersey.

Sponsor
Abramson Cancer Center at Penn Medicine
Study ID
NCT06870617
Status
Recruiting
Apply to this trial

Conditions

  • Advanced Cancer
  • Geriatric Assessment
  • Toxicity

Eligibility Criteria

Sex
ALL
Age
70 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Practical Geriatric Assessment — OTHER
    The PGA will be administered via the electronic health record (EHR), available for patients to complete independently prior to an initial medical oncology visit, or during the visit with staff assistance. Results from the PGA will be shared automatically with clinical teams via the EHR, including a Best Practice Alert highlighting any identified geriatric impairment(s) and ASCO's recommendation for PGA-adapted care.
  • Correlation of body composition PGA and step count with outcomes — OTHER
    Monitoring of step counts (measured via FitBit) and body composition (measured via standard abdominal CT scans)

Study Details

The use of a geriatric assessment to inform oncologic care for older persons with cancer is an evidence-based practice that improves patient-clinician communication, reduces treatment-related toxicity, and is recommended by national guidelines. However, the implementation of a geriatric assessment can be time-consuming and burdensome, leading to suboptimal use in clinical practice. Developed and endorsed by the American Society for Clinical Oncology (ASCO), the Practical Geriatric Assessment (PGA) is designed to improve clinical usability and adoption, but its implementation in real-world settings has not been evaluated. The PACE-70 study aims to evaluate PGA implementation and resultant chemotherapy dose modification among older adults with advanced cancer treated in a community setting. An exploratory aim will evaluate how the PGA, body composition (via abdominal computed tomography scan) and step count monitoring (via FitBit) correlate with chemotherapy toxicity and other clinical outcomes.

Key Dates

Start date
Jul 1, 2025
Status verified
Jul 2025
Primary completion
Jul 1, 2026
Completion
Oct 1, 2026

Study Design

Enrollment
150 participants (estimated)

Arms

  • Arm: PGA Implementation Cohort (n=150)
    All eligible patients will be evaluated on their completion rates of the practical geriatric assessment.
  • Arm: Correlative analyses cohort (n=100)

Primary Outcome Measure

Implementation of the PGA [ Time Frame: 14 days of initial oncology visit ]

Central Contacts

Locations (3)

FacilityCityStateZIPSite coordinators
Penn Medicine Princeton Medical CenterPrincetonNew Jersey08540
Ramy Sedhom, M.D.
[email protected]
9178164858
Lancaster General HospitalLancasterPennsylvania17602
Efrat Dotan, M.D.
[email protected]
7175449401
Pennsylvania HospitalPhiladelphiaPennsylvania19107
Samuel Takvorian, M.D., M.S.
[email protected]
2156626319

Find similar trials in Princeton, NJ

By research site
Penn Medicine Princeton Medical Center· Princeton, NJLancaster General Hospital· Lancaster, PAPennsylvania Hospital· Philadelphia, PA

Related Studies